Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupivacaine + lidocaine is a clinician-administered combination of two amide local anesthetics used for local and regional anesthesia, including infiltration and nerve or fascial-plane blocks. Both agents inhibit voltage-gated sodium channels in excitable tissue, suppressing sodium-dependent initiation and propagation of nerve impulses; the combination is used to provide regional analgesia while balancing lidocaine's relatively rapid onset with bupivacaine's longer anesthetic duration. It is not a single globally standardized or uniquely marketed fixed-dose product; published studies commonly describe separately supplied injectable solutions mixed or administered together for a procedure. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3eefbefe-78ae-4f2d-9be6-3f79eadcff86))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + lidocaine.